Orchestra BioMed will use the funding to support continued late-stage clinical development of its Virtue sirolimus-eluting balloon (SEB) to treat artery disease and BackBeat cardiac neuromodulation therapy (CNT)
The post Orchestra BioMed secures $41m funding for cardiovascular product candidates appeared first on Compelo Medical Devices.